DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,042 filers reported holding DANAHER CORPORATION in Q3 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,294,586 | -48.0% | 5,218 | -44.4% | 0.10% | -63.2% |
| Q4 2022 | $2,489,640 | -81.9% | 9,380 | -79.2% | 0.28% | -67.1% |
| Q3 2021 | $13,761,000 | +602.1% | 45,201 | +518.9% | 0.85% | +633.6% |
| Q2 2021 | $1,960,000 | -66.4% | 7,303 | -71.8% | 0.12% | -64.4% |
| Q1 2021 | $5,829,000 | +95.3% | 25,897 | +53.4% | 0.33% | +107.6% |
| Q2 2020 | $2,984,000 | +447.5% | 16,877 | +328.8% | 0.16% | +214.0% |
| Q1 2020 | $545,000 | -61.2% | 3,936 | -57.0% | 0.05% | -31.5% |
| Q4 2019 | $1,406,000 | -45.8% | 9,164 | -49.0% | 0.07% | -70.6% |
| Q3 2019 | $2,593,000 | +878.5% | 17,954 | +472.5% | 0.25% | +148.0% |
| Q2 2017 | $265,000 | -43.0% | 3,136 | -42.4% | 0.10% | -51.2% |
| Q1 2017 | $465,000 | +42.6% | 5,440 | +54.9% | 0.20% | -78.0% |
| Q4 2015 | $326,000 | +30.9% | 3,512 | +19.9% | 0.93% | +187.3% |
| Q1 2015 | $249,000 | -52.6% | 2,930 | -52.2% | 0.32% | -73.0% |
| Q4 2014 | $525,000 | -30.0% | 6,128 | -37.9% | 1.20% | +83.3% |
| Q3 2014 | $750,000 | -57.3% | 9,871 | -55.7% | 0.65% | -41.6% |
| Q2 2014 | $1,756,000 | +199.1% | 22,305 | +193.3% | 1.12% | -11.7% |
| Q4 2013 | $587,000 | – | 7,606 | – | 1.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |